CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 40 filers reported holding CORVUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,782,399 | -36.2% | 3,275,616 | 0.0% | 1.67% | -14.8% |
| Q2 2023 | $7,501,161 | +151.6% | 3,275,616 | 0.0% | 1.96% | +111.0% |
| Q1 2023 | $2,980,811 | +7.1% | 3,275,616 | 0.0% | 0.93% | +0.1% |
| Q4 2022 | $2,784,274 | +3.8% | 3,275,616 | 0.0% | 0.93% | +26.4% |
| Q3 2022 | $2,683,000 | -17.3% | 3,275,616 | 0.0% | 0.74% | -12.9% |
| Q2 2022 | $3,243,000 | -39.6% | 3,275,616 | 0.0% | 0.84% | -15.1% |
| Q1 2022 | $5,373,000 | -31.9% | 3,275,616 | 0.0% | 0.99% | -17.5% |
| Q4 2021 | $7,894,000 | -50.2% | 3,275,616 | 0.0% | 1.20% | -40.8% |
| Q3 2021 | $15,854,000 | +81.3% | 3,275,616 | 0.0% | 2.04% | +12.0% |
| Q2 2021 | $8,746,000 | -13.3% | 3,275,616 | 0.0% | 1.82% | +12.4% |
| Q1 2021 | $10,089,000 | -13.5% | 3,275,616 | 0.0% | 1.62% | -33.3% |
| Q4 2020 | $11,661,000 | -11.2% | 3,275,616 | 0.0% | 2.42% | -30.0% |
| Q3 2020 | $13,135,000 | +47.4% | 3,275,616 | 0.0% | 3.46% | +87.8% |
| Q2 2020 | $8,910,000 | +28.9% | 3,275,616 | 0.0% | 1.84% | +6.9% |
| Q1 2020 | $6,912,000 | -61.2% | 3,275,616 | 0.0% | 1.72% | -52.6% |
| Q4 2019 | $17,819,000 | +80.7% | 3,275,616 | 0.0% | 3.64% | +84.6% |
| Q3 2019 | $9,860,000 | -19.5% | 3,275,616 | 0.0% | 1.97% | -13.2% |
| Q2 2019 | $12,251,000 | -7.0% | 3,275,616 | 0.0% | 2.27% | -10.9% |
| Q1 2019 | $13,168,000 | +9.5% | 3,275,616 | 0.0% | 2.55% | +1.2% |
| Q4 2018 | $12,022,000 | -57.2% | 3,275,616 | 0.0% | 2.52% | -43.0% |
| Q3 2018 | $28,105,000 | -21.9% | 3,275,616 | 0.0% | 4.42% | -19.7% |
| Q2 2018 | $35,966,000 | +5.8% | 3,275,616 | 0.0% | 5.51% | -15.0% |
| Q1 2018 | $33,991,000 | +22.1% | 3,275,616 | +21.9% | 6.48% | -1.9% |
| Q4 2017 | $27,841,000 | -35.0% | 2,687,381 | 0.0% | 6.61% | -39.6% |
| Q3 2017 | $42,837,000 | +31.7% | 2,687,381 | 0.0% | 10.94% | +43.4% |
| Q2 2017 | $32,517,000 | -41.7% | 2,687,381 | 0.0% | 7.63% | -44.4% |
| Q1 2017 | $55,817,000 | +45.2% | 2,687,381 | 0.0% | 13.73% | +29.8% |
| Q4 2016 | $38,430,000 | -13.1% | 2,687,381 | 0.0% | 10.58% | +27.0% |
| Q3 2016 | $44,207,000 | +53.8% | 2,687,381 | 0.0% | 8.33% | +77.1% |
| Q2 2016 | $28,742,000 | -1.7% | 2,687,381 | 0.0% | 4.70% | -11.8% |
| Q1 2016 | $29,225,000 | – | 2,687,381 | – | 5.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 3,275,616 | $28,105,000 | 4.42% |
| Novo Holdings A/S | 4,420,516 | $37,928,000 | 3.01% |
| BVF INC/IL | 1,890,507 | $16,221,000 | 1.42% |
| Orbimed Advisors | 5,967,584 | $51,202,000 | 0.62% |
| COWEN INC. | 588,706 | $5,051,000 | 0.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,000 | $710,000 | 0.34% |
| SPHERA FUNDS MANAGEMENT LTD. | 321,430 | $2,758,000 | 0.32% |
| EcoR1 Capital, LLC | 351,401 | $3,015,000 | 0.27% |
| Rock Springs Capital Management LP | 575,000 | $4,934,000 | 0.18% |
| Hikari Power Ltd | 32,090 | $275,000 | 0.03% |